180 related articles for article (PubMed ID: 31642372)
1. Prediction of bortezomib-induced peripheral neuropathy with the R-R interval variation of the electrocardiogram in plasma cell myeloma: a retrospective study.
Nishiwaki U; Yokote T; Hatooka J; Miyoshi T; Iwaki K; Masuda Y; Fujimoto M; Ueda M; Kinoshita Y; Arita Y; Shimizu M; Yamada T; Tanabe K; Akioka T; Imagawa A
Leuk Lymphoma; 2020 Mar; 61(3):707-713. PubMed ID: 31642372
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach.
Yang Y; Zhao B; Lan H; Sun J; Wei G
Crit Rev Oncol Hematol; 2024 May; 197():104353. PubMed ID: 38615869
[TBL] [Abstract][Full Text] [Related]
4. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
Yan W; Wu Z; Zhang Y; Hong D; Dong X; Liu L; Rao Y; Huang L; Zhang X; Wu J
Biomed Pharmacother; 2021 Oct; 142():112068. PubMed ID: 34463262
[TBL] [Abstract][Full Text] [Related]
5. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients.
Zhang Y; Zhang H; Wang J; Wei X; Qu YI; Xu F; Zhang L
Oncol Res; 2024; 32(5):955-963. PubMed ID: 38686049
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.
Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB
Hematol Oncol; 2020 Aug; 38(3):229-243. PubMed ID: 31873944
[TBL] [Abstract][Full Text] [Related]
7. Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Hashimoto N; Yokoyama K; Sadahira K; Ueda T; Tsukada Y; Okamoto S
Int J Hematol; 2012 Dec; 96(6):758-63. PubMed ID: 23179905
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Argyriou AA; Iconomou G; Kalofonos HP
Blood; 2008 Sep; 112(5):1593-9. PubMed ID: 18574024
[TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
Cavaletti G; Jakubowiak AJ
Leuk Lymphoma; 2010 Jul; 51(7):1178-87. PubMed ID: 20497001
[TBL] [Abstract][Full Text] [Related]
10. Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.
Zhi WI; Ingram E; Li SQ; Chen P; Piulson L; Bao T
Integr Cancer Ther; 2018 Dec; 17(4):1079-1086. PubMed ID: 30027756
[TBL] [Abstract][Full Text] [Related]
11. [Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
Zhang LL; Wang YH; Shao ZH; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):480-484. PubMed ID: 28446297
[TBL] [Abstract][Full Text] [Related]
12. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
Kumar SK; Laubach JP; Giove TJ; Quick M; Neuwirth R; Yung G; Rajkumar SV; Richardson PG
Br J Haematol; 2017 Sep; 178(5):756-763. PubMed ID: 28591409
[TBL] [Abstract][Full Text] [Related]
13. Foot drop in patients treated with bortezomib - a case series and review of the literature.
Vaxman I; Mauerman ML; Gatt ML; Berger T; Gertz MA
Leuk Lymphoma; 2022 Mar; 63(3):722-728. PubMed ID: 34702127
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
Lee SE; Choi K; Han S; Lee J; Hong T; Park GJ; Yim DS; Min CK
Anticancer Drugs; 2017 Jul; 28(6):660-668. PubMed ID: 28430745
[TBL] [Abstract][Full Text] [Related]
15. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC
Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516
[TBL] [Abstract][Full Text] [Related]
16. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.
Maschio M; Maialetti A; Marchesi F; Gumenyuk S; Pisani F; Papa E; Galiè E; Koudriavtseva T; Graziano G; Giannarelli D; Mengarelli A
Integr Cancer Ther; 2022; 21():15347354221114142. PubMed ID: 35866451
[TBL] [Abstract][Full Text] [Related]
18. Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK; Lonial S; Harvey RD
JCO Oncol Pract; 2023 Sep; 19(9):793-798. PubMed ID: 37418682
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.
Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153
[TBL] [Abstract][Full Text] [Related]
20. Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Yamamoto S; Egashira N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
